Literature DB >> 15055450

Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions.

Don J Mahad1, Corinna Trebst, Pia Kivisäkk, Susan M Staugaitis, Barbara Tucky, Tao Wei, Claudia F Lucchinetti, Hans Lassmann, Richard M Ransohoff.   

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the CNS. A recent study identified 4 patterns of demyelination in active MS lesions. The characteristics of pattern II lesions suggested a primary inflammatory mechanism of myelin injury, while pattern III lesions showed features consistent with dying-back oligodendrogliopathy. The recruitment, differentiation, and activation of mononuclear phagocytes are dependent on the expression of chemokine receptors. Using immunohistochemistry we quantified cellular expression of CCR1 and CCR5 in pattern II (n = 21) and pattern III (n = 17) lesion areas of differing demyelinating activity. Infiltrating monocytes in both lesion patterns co-expressed CCR1 and CCR5, suggesting conserved mechanisms of monocyte recruitment into the CNS. In pattern II lesions, the number of cells expressing CCR1 significantly decreased while CCR5 increased in late active compared with early active demyelinating regions. In striking contrast, numbers of cells expressing CCR1 and CCR5 were equal in all regions of pattern III lesions. As hypoxia-like mechanisms may play a role in pattern III lesions, we extended these studies to white matter infarcts (n = 7) in which the expression of CCR1 better resembled pattern III than pattern II lesions. As judged by mononuclear phagocyte chemokine receptor expression, there appear to be distinct tissue environments in pattern II and III MS lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15055450     DOI: 10.1093/jnen/63.3.262

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  25 in total

1.  Haplotypes within genes of beta-chemokines in 17q11 are associated with multiple sclerosis: a second phase study.

Authors:  Tamara Vyshkina; Bernadette Kalman
Journal:  Hum Genet       Date:  2005-08-03       Impact factor: 4.132

2.  CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro.

Authors:  Eroboghene E Ubogu; Melissa K Callahan; Barbara H Tucky; Richard M Ransohoff
Journal:  Cell Immunol       Date:  2007-01-25       Impact factor: 4.868

Review 3.  Chemokines and chemokine receptors: update on utility and challenges for the clinician.

Authors:  Ishan Roy; Douglas B Evans; Michael B Dwinell
Journal:  Surgery       Date:  2014-02-08       Impact factor: 3.982

4.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

5.  CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis.

Authors:  LiPing Liu; Abdelmadjid Belkadi; Lindsey Darnall; Taofang Hu; Caitlin Drescher; Anne C Cotleur; Dolly Padovani-Claudio; Tao He; Karen Choi; Thomas E Lane; Robert H Miller; Richard M Ransohoff
Journal:  Nat Neurosci       Date:  2010-02-14       Impact factor: 24.884

6.  Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta.

Authors:  Latt Latt Aung; Patricia Fitzgerald-Bocarsly; Suhayl Dhib-Jalbut; Konstantin Balashov
Journal:  J Neuroimmunol       Date:  2010-09-14       Impact factor: 3.478

Review 7.  Monocyte recruitment during infection and inflammation.

Authors:  Chao Shi; Eric G Pamer
Journal:  Nat Rev Immunol       Date:  2011-10-10       Impact factor: 53.106

8.  Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Authors:  Imke Metz; Stephen D Weigand; Bogdan F G Popescu; Josa M Frischer; Joseph E Parisi; Yong Guo; Hans Lassmann; Wolfgang Brück; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

Review 9.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

Review 10.  Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?

Authors:  Carine Savarin-Vuaillat; Richard M Ransohoff
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.